Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.61 |
| ▸ | FAP | Q12884 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5612545 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4456750 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL3602584 | 0.98 | DPP4 (0.97) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL5013082 | 0.98 | DPP4 (0.97) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL23082607 | 0.88 | DPP4 (0.79) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL13525327 | 0.86 | DPP4 (0.75) | DPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL18281110 | 0.85 | DPP4 (0.73) | DPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL5068240 | 0.85 | DPP4 (0.73) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL8290707 | 0.83 | DPP4 (0.71) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL15636202 | 0.83 | DPP4 (1.00) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620091-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-03-31 | — | — | EP | claimed |
| US-7655684-B2 | 1-(Urea-, thiourea- and cyanoguanidine-methylene)benzyl)imidaoles, treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson's disease and Huntington's disease | PROBIODRUG AG (DE) | 2010-02-02 | — | — | US | claimed |
| US-7371871-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2008-05-13 | — | — | US | claimed |
| EP-1377278-B1 | TREATMENT OF TYPE 2 DIABETES WITH INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | FERRING BV (NL) | 2006-11-02 | — | — | EP | claimed |
| US-7115650-B1 | Compositions for improving fertility | FERRING BV (NL) | 2006-10-03 | — | — | US | claimed |
| US-20050171112-A1 | Combinations useful for the treatment of neuronal disorders | PROBIODRUG AG | 2005-08-04 | — | — | US | claimed |
| US-20050137142-A1 | Combinations useful for the treatment of neuronal disorders | PROBIODRUG AG | 2005-06-23 | — | — | US | claimed |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2004-11-11 | — | — | US | claimed |
| US-20040209891-A1 | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV | FERRING BV (NL) | 2004-10-21 | — | — | US | claimed |
| US-20030166578-A1 | COMBINATIONS OD DIPEPTIDYL PEPTIDASE IV INHIBITORS AND OTHER ANTIDIABETIC AGENTS FOR THE TREATMENT OF DIABETES MELLITUS | SMITHKLINE BEECHAM CORPORATION | 2003-09-04 | — | — | US | claimed |
| EP-1292300-A1 | COMBINATIONS OD DIPEPTIDYL PEPTIDASE IV INHIBITORS AND OTHER ANTIDIABETIC AGENTS FOR THE TREATMENT FO DIABETE MELLITUS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-19 | — | — | EP | claimed |
| WO-2001097808-A1 | COMBINATIONS OF DEPEPTIDYL PEPTIDASE IV INHIBITORS AND OTHER ANTIDIABETIC AGENTS FOR THE TREATMENT OF DIABETE MELLITUS | SMITHKLINE BEECHAM PLC (GB) | 2001-12-27 | — | — | WO | claimed |
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-6521644-B1 | Treatment subnormal development or dwarfism; administering dipeptidyl peptidase IV inhibitor | FERRING BV (NL) | 2003-02-18 | — | — | US | disclosed |
| WO-2001097808-A1 | COMBINATIONS OF DEPEPTIDYL PEPTIDASE IV INHIBITORS AND OTHER ANTIDIABETIC AGENTS FOR THE TREATMENT OF DIABETE MELLITUS | SMITHKLINE BEECHAM PLC (GB) | 2001-12-27 | — | — | WO | disclosed |
| EP-1162969-A2 | COMPOSITIONS FOR IMPROVING FERTILITY | Ferring BV (NL) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056296-A2 | COMPOSITIONS FOR IMPROVING FERTILITY | FERRING BV (NL) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171112-A1 | Combinations useful for the treatment of neuronal disorders | MME, DNPEP, DPP4 | DPP4 3/4885DPP8 20/4885DPP9 39/4885 |
| US-20040209891-A1 | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | DPP4 2016/4885DPP8 2576/4885DPP9 2961/4885 |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | DPP4 2056/4885DPP8 2739/4885DPP9 1376/4885 |
| US-20050137142-A1 | Combinations useful for the treatment of neuronal disorders | MME, DNPEP, DPP4 | DPP4 3/4885DPP8 22/4885DPP9 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.